US4853332A
(en)
|
1982-10-19 |
1989-08-01 |
Cetus Corporation |
Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
|
FI82266C
(fi)
|
1982-10-19 |
1991-02-11 |
Cetus Corp |
Foerfarande foer framstaellning av il-2 -mutein.
|
US4518584A
(en)
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
US4530787A
(en)
|
1984-03-28 |
1985-07-23 |
Cetus Corporation |
Controlled oxidation of microbially produced cysteine-containing proteins
|
US4572798A
(en)
|
1984-12-06 |
1986-02-25 |
Cetus Corporation |
Method for promoting disulfide bond formation in recombinant proteins
|
CA1340265C
(en)
|
1985-01-18 |
1998-12-15 |
Kirston E. Koths |
Oxidation resistant muteins
|
US5116943A
(en)
|
1985-01-18 |
1992-05-26 |
Cetus Corporation |
Oxidation-resistant muteins of Il-2 and other protein
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
US4766106A
(en)
|
1985-06-26 |
1988-08-23 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polymer conjugation
|
US4816440A
(en)
|
1985-09-26 |
1989-03-28 |
Cetus Corporation |
Stable formulation of biologically active proteins for parenteral injection
|
US5425940A
(en)
|
1986-04-09 |
1995-06-20 |
Cetus Oncology Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
US4863727A
(en)
|
1986-04-09 |
1989-09-05 |
Cetus Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
US5098702A
(en)
|
1986-04-09 |
1992-03-24 |
Cetus Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
US4894226A
(en)
|
1986-11-14 |
1990-01-16 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
|
AU3285989A
(en)
|
1987-11-25 |
1989-06-14 |
Cetus Corporation |
Treatment of infections caused by a primary immunodeficiency with interleukin-2
|
US5066489A
(en)
|
1988-03-28 |
1991-11-19 |
Cetus Corporation |
Combination therapy of IL-2 and DTIC for the treatment of melanoma
|
US4902502A
(en)
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
US5153310A
(en)
|
1989-02-28 |
1992-10-06 |
Du Pont Merck Pharmaceutical Company |
Il-2 analogs containing n-linked glycosylation sites
|
NZ234674A
(en)
|
1989-08-02 |
1992-02-25 |
Seragen Inc |
Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
|
US5660827A
(en)
|
1992-03-05 |
1997-08-26 |
Board Of Regents, The University Of Texas System |
Antibodies that bind to endoglin
|
US5229109A
(en)
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
WO1997003703A1
(en)
|
1995-07-21 |
1997-02-06 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
|
DK0808367T3
(da)
*
|
1995-02-10 |
2007-11-05 |
Millennium Pharm Inc |
Vaskulære slimhindeaddressiner samt anvendelse deraf
|
US20040115128A1
(en)
|
1995-09-08 |
2004-06-17 |
Schnitzer Jan E. |
Targeting endothelium for tissue-specific delivery of agents
|
EP1442750B1
(en)
|
1997-11-20 |
2012-08-01 |
Vical Incorporated |
Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
|
JP2001523480A
(ja)
|
1997-11-20 |
2001-11-27 |
バイカル インコーポレイテッド |
サイトカイン発現ポリヌクレオチドおよびそれらの組成物を用いた癌の処置
|
US6232287B1
(en)
|
1998-03-13 |
2001-05-15 |
The Burnham Institute |
Molecules that home to various selected organs or tissues
|
US6455677B1
(en)
|
1998-04-30 |
2002-09-24 |
Boehringer Ingelheim International Gmbh |
FAPα-specific antibody with improved producibility
|
DZ2788A1
(fr)
|
1998-05-15 |
2003-12-01 |
Bayer Ag |
Agonistes et antagonistes selectifs à IL-2.
|
US6955807B1
(en)
|
1998-05-15 |
2005-10-18 |
Bayer Pharmaceuticals Corporation |
IL-2 selective agonists and antagonists
|
US7138103B2
(en)
|
1998-06-22 |
2006-11-21 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
ES2207278T3
(es)
|
1998-07-28 |
2004-05-16 |
Micromet Ag |
Heterominicuerpos.
|
US6294349B1
(en)
|
1999-03-01 |
2001-09-25 |
University Of Mississippi Medical Ctr. |
Method of diagnosing and monitoring malignant breast carcinomas
|
US6348192B1
(en)
|
1999-05-11 |
2002-02-19 |
Bayer Corporation |
Interleukin-2 mutein expressed from mammalian cells
|
CZ305123B6
(cs)
|
1999-10-04 |
2015-05-13 |
Novartis Vaccines And Diagnostics, Inc. |
Způsob výroby kapalného farmaceutického prostředku
|
AU2001227966A1
(en)
|
2000-01-20 |
2001-07-31 |
Chiron Corporation |
Methods for treating tumors
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
US6579521B2
(en)
|
2000-10-20 |
2003-06-17 |
Chiron Corporation |
Methods of therapy for HIV infection
|
CA2449517A1
(en)
|
2001-06-08 |
2002-12-19 |
Utah Ventures Ii, L.P. |
Tissue-specific endothelial membrane proteins
|
EP1476180A4
(en)
|
2001-08-13 |
2005-04-20 |
Univ Southern California |
INTERLEUKIN-2 MUTANTS WITH REDUCED TOXICITY
|
US20020187512A1
(en)
|
2001-09-10 |
2002-12-12 |
Nagem Ronaldo Alves Pinto |
Crystal structure of human interleukin-22
|
US7186804B2
(en)
|
2001-12-04 |
2007-03-06 |
Emd Lexigen Research Center Corp. |
IL-2 fusion proteins with modulated selectivity
|
DK1576112T3
(da)
|
2002-01-18 |
2012-06-25 |
Zymogenetics Inc |
Cytokin-receptor zcytor17-multimerer
|
ATE466085T1
(de)
|
2002-09-09 |
2010-05-15 |
Hanall Pharmaceutical Co Ltd |
Protease-resistente modifizierte interferon alpha polypeptide
|
EP3299393A1
(en)
|
2002-11-08 |
2018-03-28 |
Ablynx N.V. |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
JP4511943B2
(ja)
|
2002-12-23 |
2010-07-28 |
ワイス エルエルシー |
Pd−1に対する抗体およびその使用
|
US20070202097A1
(en)
*
|
2003-03-10 |
2007-08-30 |
Krissansen Geoffrey W |
Monoclonal Antibodies That Recognise Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1), Soluble Madcam-1 And Uses Thereof
|
US7569215B2
(en)
|
2003-07-18 |
2009-08-04 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
DE602004031341D1
(de)
|
2003-07-21 |
2011-03-24 |
Transgene Sa |
Multifunktionelle cytokine
|
DK1944318T3
(da)
|
2003-07-21 |
2011-06-14 |
Transgene Sa |
Multifunktionelle cytokiner
|
KR100632985B1
(ko)
|
2003-07-26 |
2006-10-11 |
메덱스젠 주식회사 |
생리활성 조절 단백질의 효능 향상 방법 및 그 예시변이체들
|
US20050069521A1
(en)
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
US8454963B2
(en)
|
2003-11-13 |
2013-06-04 |
Musc Foundation For Research Development |
Tissue targeted complement modulators
|
EP1709196A4
(en)
|
2003-12-22 |
2008-10-29 |
Novartis Vaccines & Diagnostic |
USE OF FC RECEPTOR POLYMORPHISMS AS DIAGNOSIS FOR STRATEGIES FOR THE TREATMENT OF IMMUNE RESPONSE DISORDERS
|
PT2177537E
(pt)
|
2004-01-09 |
2011-12-13 |
Pfizer |
Anticorpos contra madcam
|
RU2006135112A
(ru)
|
2004-03-05 |
2008-04-10 |
Чирон Корпорейшн (Us) |
Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам
|
CA2566363C
(en)
|
2004-05-19 |
2014-12-16 |
Avidex Ltd |
High affinity ny-eso t cell receptor
|
WO2005117977A2
(en)
|
2004-06-02 |
2005-12-15 |
Sidney Kimmel Cancer Center |
Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface
|
US20070014765A1
(en)
|
2005-01-27 |
2007-01-18 |
Chiron Corporation |
Methods for treating renal cell carcinoma
|
BRPI0607351A2
(pt)
|
2005-02-15 |
2009-09-01 |
Novartis Vaccines & Diagnostic |
métodos para tratamento de linfomas empregando uma combinação de agente quimioterapêutico e il-2 e opcionalmente um anticorpo anti-cd20
|
WO2006096461A2
(en)
*
|
2005-03-08 |
2006-09-14 |
Pharmacia & Upjohn Company Llc |
Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
|
KR101339628B1
(ko)
|
2005-05-09 |
2013-12-09 |
메다렉스, 인코포레이티드 |
예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
|
NZ581779A
(en)
|
2005-05-17 |
2011-09-30 |
Univ Connecticut |
Composition and methods for immunomodulation in an organism comprising interleukin-15 polypeptide and interleukin-15 receptor subunit A polypeptide complex
|
DE602006017373D1
(de)
*
|
2005-07-08 |
2010-11-18 |
Pfizer Ltd |
Madcam-antikörper
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
PT1999154E
(pt)
|
2006-03-24 |
2013-01-24 |
Merck Patent Gmbh |
Domínios proteicos heterodiméricos modificados
|
NZ572773A
(en)
|
2006-06-06 |
2011-11-25 |
Crucell Holland Bv |
Human binding molecules having killing activity against staphylococci and uses thereof
|
WO2008003473A2
(en)
|
2006-07-06 |
2008-01-10 |
Merck Patent Gmbh |
Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
|
US8470323B2
(en)
|
2007-01-09 |
2013-06-25 |
The Trustees Of The University Of Pennsylvania |
Drug delivery to human tissues by single chain variable region antibody fragments cloned by phage display
|
WO2008097439A2
(en)
|
2007-02-07 |
2008-08-14 |
The Trustees Of The University Of Pennsylvania |
Anti-autoimmune antibodies for treatment of pemphigus
|
EP3269384A1
(en)
|
2007-03-07 |
2018-01-17 |
Uti Limited Partnership |
Compositions and methods for the prevention and treatment of autoimmune conditions
|
WO2008124858A2
(en)
|
2007-04-11 |
2008-10-23 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. |
Targeted receptor
|
US20080260820A1
(en)
|
2007-04-19 |
2008-10-23 |
Gilles Borrelly |
Oral dosage formulations of protease-resistant polypeptides
|
WO2009002380A2
(en)
|
2007-06-26 |
2008-12-31 |
The Trustees Of The University Of Pennsylvania |
Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies
|
WO2009061853A2
(en)
|
2007-11-05 |
2009-05-14 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (il-2) polypeptides
|
EP2225397A4
(en)
|
2007-11-28 |
2011-08-17 |
Univ Montreal |
PD-1 MODULATION AND USES THEREOF
|
DE102008023820A1
(de)
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
JP2012501670A
(ja)
|
2008-09-12 |
2012-01-26 |
アイシス・イノベーション・リミテッド |
Pd−1特異抗体およびその使用
|
CA2736816C
(en)
|
2008-09-12 |
2018-05-22 |
Isis Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
CN107056951A
(zh)
|
2008-10-02 |
2017-08-18 |
阿帕特夫研究和发展有限公司 |
Cd86拮抗物多靶点结合蛋白
|
US8343497B2
(en)
|
2008-10-12 |
2013-01-01 |
The Brigham And Women's Hospital, Inc. |
Targeting of antigen presenting cells with immunonanotherapeutics
|
MX2011004193A
(es)
|
2008-10-21 |
2011-05-24 |
Merck Patent Gmbh |
Tratamiento de cancer con radiacion e inmunocitosinas.
|
AU2010206840B2
(en)
|
2009-01-21 |
2015-02-05 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
WO2010117423A2
(en)
|
2009-03-31 |
2010-10-14 |
Duke University |
A METHOD FOR TREATING A PATIENT HAVING OR AT RISK FOR DEVELOPING A DISORDER ASSOCIATED WITH DECREASED EXPRESSION OF ß2 ADRENERGIC RECEPTORS OR NEED FOR INCREASED ß2 ADRENERGIC RECEPTOR ACTIVITY
|
NZ714757A
(en)
|
2009-08-14 |
2018-07-27 |
Us Gov Health & Human Services |
Use of il-15 to increase thymic output and to treat lymphopenia
|
CU23734A1
(es)
|
2009-11-27 |
2011-11-15 |
Centro Inmunologia Molecular |
Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
|
AU2010343056A1
(en)
|
2009-12-29 |
2012-08-02 |
Emergent Product Development Seattle, Llc |
Ron binding constructs and methods of use thereof
|
NZ602294A
(en)
|
2010-03-10 |
2015-04-24 |
Genmab As |
Monoclonal antibodies against c-met
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
WO2011110604A1
(en)
|
2010-03-11 |
2011-09-15 |
Ucb Pharma, S.A. |
Pd-1 antibody
|
WO2012058768A1
(en)
|
2010-11-05 |
2012-05-10 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
PT2637694T
(pt)
|
2010-11-12 |
2021-05-05 |
Nektar Therapeutics |
Conjugados de uma fração de il-2 e um polímero
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
WO2012088446A1
(en)
|
2010-12-22 |
2012-06-28 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
TWI666027B
(zh)
|
2011-02-10 |
2019-07-21 |
羅齊克雷雅公司 |
突變介白素-2多肽
|
US20120207733A1
(en)
|
2011-02-14 |
2012-08-16 |
Allergan, Inc. |
Treating a Disease of Hyperproliferation Using Retargeted Endopeptidases
|
WO2012119093A1
(en)
|
2011-03-03 |
2012-09-07 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
CA2828811C
(en)
|
2011-03-03 |
2021-09-21 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
EP2683395B1
(en)
|
2011-03-11 |
2018-08-01 |
Assistance Publique - Hôpitaux de Paris |
Use of low dose il-2 for treating type 1 diabetes
|
ES2811624T3
(es)
|
2011-03-11 |
2021-03-12 |
Hopitaux Paris Assist Publique |
Régimen de dosificación de IL-2 para tratar lupus eritematoso sistémico
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
WO2012163519A1
(en)
|
2011-05-27 |
2012-12-06 |
Dutalys |
Antibodies with improved folding stability
|
CA2840409A1
(en)
|
2011-06-28 |
2013-01-03 |
Whitehead Institute For Biomedical Research |
Using sortases to install click chemistry handles for protein ligation
|
EP2742953B1
(en)
|
2011-08-11 |
2021-09-22 |
ONO Pharmaceutical Co., Ltd. |
Therapeutic agent for autoimmune diseases comprising pd-1 agonist
|
US20140248372A1
(en)
|
2011-09-19 |
2014-09-04 |
Emory University |
Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
|
BR112014010580B1
(pt)
|
2011-11-04 |
2021-01-12 |
Zymeworks, Inc. |
constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
|
EP2780364A2
(en)
|
2011-11-18 |
2014-09-24 |
Eleven Biotherapeutics, Inc. |
Proteins with improved half-life and other properties
|
CN110078818B
(zh)
|
2012-04-27 |
2023-12-29 |
诺和诺德股份有限公司 |
人cd30配体抗原结合蛋白
|
WO2013177187A2
(en)
|
2012-05-22 |
2013-11-28 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
|
WO2013189516A1
(en)
|
2012-06-18 |
2013-12-27 |
Apeiron Biologics Ag |
Method for treating a gd2 positive cancer
|
WO2014004586A1
(en)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
CA2876293C
(en)
|
2012-06-27 |
2023-10-10 |
Arthrogen B.V. |
Combination for treating an inflammatory disorder
|
WO2014012082A2
(en)
|
2012-07-13 |
2014-01-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design an constructs
|
CN103566377A
(zh)
|
2012-07-18 |
2014-02-12 |
上海博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
MY175687A
(en)
|
2012-08-07 |
2020-07-06 |
Roche Glycart Ag |
Composition comprising two antibodies engineered to have reduced and increased effector function
|
JP6174710B2
(ja)
|
2012-12-05 |
2017-08-02 |
ナショナル チュン シン ユニバーシティ |
ケモカイン−サイトカイン融合タンパク質およびその利用
|
WO2014100014A1
(en)
|
2012-12-17 |
2014-06-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Super-2 complexes with antibody to augment il-2 therapy
|
EP2950814A4
(en)
|
2013-01-31 |
2016-06-08 |
Univ Jefferson |
PD-L1 AND PD-L2 BASED FUSION PROTEINS AND USES THEREOF
|
US20150259416A1
(en)
|
2014-03-12 |
2015-09-17 |
Biocrine Ab |
Methods for treating and/or limiting development of diabetes
|
US9546203B2
(en)
|
2013-03-14 |
2017-01-17 |
Amgen Inc. |
Aglycosylated Fc-containing polypeptides with cysteine substitutions
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
EA201890895A1
(ru)
|
2013-03-15 |
2019-02-28 |
Зинджения, Инк. |
Мультивалентные и моновалентные мультиспецифические комплексы и их применение
|
WO2014150600A2
(en)
|
2013-03-15 |
2014-09-25 |
Angelica Therapeutics, Inc. |
Modified toxins
|
AU2014262469B2
(en)
|
2013-05-10 |
2019-11-14 |
Whitehead Institute For Biomedical Research |
Protein modification of living cells using sortase
|
CN104395342B
(zh)
|
2013-06-06 |
2017-07-04 |
合肥立方制药股份有限公司 |
人源抗纤连蛋白ed‑b结构域的抗体及其用途
|
WO2015066543A1
(en)
|
2013-11-01 |
2015-05-07 |
Board Of Regents, The University Of Texas System |
Targeting her2 and her3 with bispecific antibodies in cancerous cells
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
AU2015215001B2
(en)
|
2014-02-06 |
2019-08-15 |
F. Hoffmann-La Roche Ag |
Interleukin-2 fusion proteins and uses thereof
|
US10323077B2
(en)
|
2014-02-10 |
2019-06-18 |
Emory University |
Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
|
EP2918285A1
(en)
|
2014-03-11 |
2015-09-16 |
Université Pierre et Marie Curie (Paris 6) |
Interleukin-2 for treating food allergy
|
JP6935195B2
(ja)
|
2014-03-11 |
2021-09-15 |
モレキュラー テンプレーツ, インク.Molecular Templates, Inc. |
結合領域、志賀毒素aサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
|
CN106659757B
(zh)
|
2014-04-24 |
2022-01-28 |
利兰斯坦福初级大学董事会 |
白介素2的超级激动剂、部分激动剂和拮抗剂
|
KR102496206B1
(ko)
|
2014-06-11 |
2023-02-06 |
몰레큘러 템플레이츠, 인코퍼레이션. |
프로테아제-절단 저항성의 시가 독소 a 서브유닛 작동체 폴리펩티드 및 이를 포함하는 세포-표적화 분자
|
EP2963057A1
(en)
|
2014-07-02 |
2016-01-06 |
Calypso Biotech SA |
Antibodies to IL-15
|
SG11201700514SA
(en)
|
2014-07-21 |
2017-02-27 |
Delinia Inc |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
AR101936A1
(es)
*
|
2014-07-31 |
2017-01-25 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas
|
CN107074947B
(zh)
|
2014-08-05 |
2021-04-09 |
马布奎斯特公司 |
结合至pd-1的免疫试剂
|
MA40094B1
(fr)
|
2014-08-06 |
2022-05-31 |
Univ Miami |
Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
|
PL3482766T3
(pl)
|
2014-08-11 |
2020-11-16 |
Delinia, Inc. |
Modyfikowane warianty il-2, które selektywnie aktywują limfocyty t regulatorowe do leczenia chorób autoimmunologicznych
|
CA2957717C
(en)
|
2014-08-12 |
2021-10-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
|
RU2710354C2
(ru)
|
2014-08-29 |
2019-12-25 |
Ф.Хоффманн-Ля Рош Аг |
Комбинированная терапия на основе нацеленных на опухоль иммуноцитокинов, содержащих вариант il-2, и антител к человеческому pd-l1
|
EP4006052A1
(en)
|
2014-10-23 |
2022-06-01 |
Singh Molecular Medicine, LLC |
Single domain antibodies directed against intracellular antigens
|
EP3233192B1
(en)
|
2014-12-15 |
2021-04-14 |
Washington University |
Compositions and methods for targeted cytokine delivery
|
US10239942B2
(en)
|
2014-12-22 |
2019-03-26 |
Pd-1 Acquisition Group, Llc |
Anti-PD-1 antibodies
|
US20160206666A1
(en)
|
2014-12-22 |
2016-07-21 |
Synlogic, Inc. |
Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
|
WO2016115168A1
(en)
|
2015-01-12 |
2016-07-21 |
Synthorx, Inc. |
Incorporation of unnatural nucleotides and methods thereof
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
SG10201913297TA
(en)
|
2015-03-13 |
2020-02-27 |
Cytomx Therapeutics Inc |
Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
|
CN107921122B
(zh)
|
2015-04-08 |
2021-08-10 |
索伦托药业有限公司 |
与cd38结合的抗体治疗剂
|
CA2975333A1
(en)
|
2015-04-22 |
2016-10-27 |
Curevac Ag |
Rna containing composition for treatment of tumor diseases
|
US20180154012A1
(en)
|
2015-05-05 |
2018-06-07 |
Rubicon Biotechnology Llc |
Cancer immunotherapeutic
|
GB201507908D0
(en)
|
2015-05-08 |
2015-06-24 |
Philogen Spa |
IL2 and TNF immunoconjugates
|
US9845345B2
(en)
|
2015-05-18 |
2017-12-19 |
Ab Initio Biotherapeutics, Inc. |
SIRP polypeptide compositions and methods of use
|
KR102526538B1
(ko)
|
2015-06-10 |
2023-04-28 |
이뮤너티바이오, 인크. |
암을 치료하기 위한 변형된 nk-92 세포
|
CA3006224A1
(en)
|
2015-06-23 |
2016-12-29 |
Memorial Sloan-Kettering Cancer Center |
Novel pd-1 immune modulating agents
|
BR112017028315A2
(pt)
|
2015-06-30 |
2018-09-04 |
Nanotics Llc |
composições e métodos relacionados com partículas de sequestrante
|
KR20180034619A
(ko)
|
2015-07-29 |
2018-04-04 |
나노틱스 엘엘씨 |
가용성 생체분자를 소거하기 위한 모듈 조성물 및 이와 관련된 방법
|
WO2017023780A1
(en)
|
2015-07-31 |
2017-02-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-drug conjugates for targeting cd56-positive tumors
|
TWI617319B
(zh)
|
2015-09-01 |
2018-03-11 |
免疫功坊股份有限公司 |
用以治療病理性血栓的融合蛋白
|
EP3347056A4
(en)
|
2015-09-11 |
2019-02-27 |
The Board of Trustees of the Leland Stanford Junior University |
BIOLOGICALLY RELEVANT ORTHOGONAL RECEPTOR / CYTOKINE PAIRS
|
AU2016332725A1
(en)
|
2015-09-29 |
2018-03-22 |
Celgene Corporation |
PD-1 binding proteins and methods of use thereof
|
AU2016332900C1
(en)
|
2015-09-29 |
2024-02-01 |
Amgen Inc. |
ASGR inhibitors
|
MA45488A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil de culture de cellules
|
MX2018004883A
(es)
|
2015-10-22 |
2018-08-01 |
Iltoo Pharma |
Composiciones farmaceuticas de il-2.
|
US20170232070A1
(en)
|
2015-10-23 |
2017-08-17 |
Richard P. Junghans |
Combination Methods for Immunotherapy
|
WO2017070561A1
(en)
|
2015-10-23 |
2017-04-27 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
CA3003969A1
(en)
|
2015-11-06 |
2017-05-11 |
Orionis Biosciences Nv |
Bi-functional chimeric proteins and uses thereof
|
WO2017087789A1
(en)
|
2015-11-19 |
2017-05-26 |
Revitope Limited |
Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
|
US10597466B2
(en)
|
2015-12-02 |
2020-03-24 |
Fred Hutchinson Cancer Research Center |
Circular tandem repeat proteins
|
WO2017096262A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
BR112018003984A2
(pt)
|
2015-12-09 |
2018-09-25 |
Hoffmann La Roche |
anticorpos
|
WO2017102010A1
(en)
|
2015-12-17 |
2017-06-22 |
Biontech Rna Pharmaceuticals Gmbh |
Novel cytokine fusion proteins
|
CN108430511B
(zh)
|
2015-12-21 |
2021-06-04 |
合肥立方制药股份有限公司 |
一种药物设计方法和获得的药物及其应用
|
US10889643B2
(en)
|
2016-01-11 |
2021-01-12 |
Universität Zürich |
Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
|
CA3008440A1
(en)
|
2016-01-11 |
2017-07-20 |
Universitat Zurich |
Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent
|
WO2017123675A1
(en)
|
2016-01-11 |
2017-07-20 |
Synlogic, Inc. |
Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
|
WO2017122180A1
(en)
|
2016-01-14 |
2017-07-20 |
Intrexon Actobiotics N.V. |
Compositions and methods for the treatment of type 1 diabetes
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
JP7220458B2
(ja)
|
2016-02-05 |
2023-02-10 |
ワシントン・ユニバーシティ |
標的サイトカインデリバリーのための組成物および方法
|
ES2877568T3
(es)
|
2016-02-05 |
2021-11-17 |
Orionis Biosciences Nv |
Agentes de unión de Clec9A
|
US10888603B2
(en)
|
2016-02-12 |
2021-01-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating cancer cells expressing tumor-associated integrins
|
EP3211000B1
(en)
|
2016-02-25 |
2019-01-30 |
Provecs Medical GmbH |
Novel immunostimulating vector system
|
WO2017153402A1
(en)
|
2016-03-07 |
2017-09-14 |
Vib Vzw |
Cd20 binding single domain antibodies
|
CN109790545A
(zh)
|
2016-03-10 |
2019-05-21 |
约翰·霍普金斯大学 |
产生不含聚集物的单体白喉毒素融合蛋白的方法和治疗用途
|
WO2017156720A1
(zh)
|
2016-03-16 |
2017-09-21 |
谢彦晖 |
糖皮质激素联合聚乙二醇修饰的白介素2治疗呼吸道疾病
|
ES2831852T3
(es)
|
2016-03-17 |
2021-06-09 |
Univ Oslo Hf |
Proteínas de fusión que se dirigen a macrófagos asociados a tumores para tratar el cáncer
|
AU2017249694B2
(en)
|
2016-04-12 |
2019-10-03 |
Philogen S.P.A. |
Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (CAR)-T cell
|
ES2864095T3
(es)
|
2016-04-15 |
2021-10-13 |
Philogen Spa |
Anticuerpo anti-tenascina no glicosilado
|
US11326182B2
(en)
|
2016-04-29 |
2022-05-10 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
JP7422480B2
(ja)
|
2016-05-04 |
2024-01-26 |
アムジエン・インコーポレーテツド |
制御性t細胞の増殖のためのインターロイキン-2変異タンパク質
|
WO2017190684A1
(zh)
|
2016-05-06 |
2017-11-09 |
王牧林 |
白细胞介素组合及其用途
|
GB201608192D0
(en)
|
2016-05-10 |
2016-06-22 |
Immunovia Ab |
Method, array and use thereof
|
EP3458485B1
(en)
|
2016-05-19 |
2021-12-29 |
The General Hospital Corporation |
Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
|
BR112018074152A8
(pt)
|
2016-05-25 |
2023-01-31 |
Hoffmann La Roche |
Métodos para determinar um regime de dosagem, métodos para tratar um indivíduo, método para otimizar o tratamento terapeuticamente, agente terapêutico e sistema de rede para determinar uma dose eficaz ou um regime de dosagem para um indivíduo sendo tratado com um agente terapêutico
|
JP2019517577A
(ja)
|
2016-05-27 |
2019-06-24 |
エトゥビクス コーポレーション |
ネオエピトープワクチン組成物及びその使用方法
|
CA3026360A1
(en)
|
2016-06-03 |
2017-12-07 |
Etubics Corporation |
Compositions and methods for the treatment of human papillomavirus (hpv)-associated diseases
|
CN110234752A
(zh)
|
2016-06-03 |
2019-09-13 |
埃特彼塞斯公司 |
用于涉及her2/neu的肿瘤疫苗接种和免疫疗法的组合物和方法
|
CA3026342A1
(en)
|
2016-06-03 |
2017-12-07 |
Etubics Corporation |
Compositions and methods for tumor vaccination using prostate cancer-associated antigens
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
WO2017220704A1
(en)
|
2016-06-22 |
2017-12-28 |
David Klatzmann |
Genetically modified t lymphocytes
|
US11141463B2
(en)
|
2016-07-11 |
2021-10-12 |
The National Institute for Biotechnology in the Negev Ltd. |
Fusion proteins with extended serum half life
|
WO2018014008A1
(en)
|
2016-07-15 |
2018-01-18 |
Etubics Corporation |
Compositions and methods for alphavirus vaccination
|
EP3484509A4
(en)
|
2016-07-15 |
2020-03-25 |
Etubics Corporation |
COMPOSITIONS AND METHODS FOR FLAVIVIRUS VACCINATION
|
GB201614093D0
(en)
|
2016-08-17 |
2016-09-28 |
Autolus Ltd |
Vector
|
IL264439B1
(en)
|
2016-08-17 |
2024-04-01 |
Factor Bioscience Inc |
A suitable viral preparation containing a synthetic messenger RNA encoding a gene editing protein for use in cancer treatment and a synthetic messenger RNA encoding a gene editing protein for use in therapy
|
CA3034266A1
(en)
|
2016-08-19 |
2018-02-22 |
Brooklyn Immunotherapeutics Llc |
Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer
|
EP3512875A2
(en)
|
2016-09-15 |
2019-07-24 |
Quadrucept Bio Limited |
Multimers, tetramers&octamers
|
JP2019531284A
(ja)
|
2016-09-19 |
2019-10-31 |
セルジーン コーポレイション |
Pd−1結合タンパク質を使用して免疫障害を治療する方法
|
WO2018053401A1
(en)
|
2016-09-19 |
2018-03-22 |
Celgene Corporation |
Methods of treating vitiligo using pd-1 binding proteins
|
AU2017331277A1
(en)
|
2016-09-23 |
2019-03-28 |
Marengo Therapeutics, Inc. |
Multispecific antibody molecules comprising lambda and kappa light chains
|
EP3519562A4
(en)
|
2016-09-29 |
2020-03-25 |
Nantkwest, Inc. |
NK-92 HLA CLASS I DEFICIENT CELLS WITH REDUCED IMMUNOGENICITY
|
CA3041334A1
(en)
|
2016-11-08 |
2018-05-17 |
Delinia, Inc. |
Il-2 variants for the treatment of autoimmune diseases
|
US20190275133A1
(en)
|
2016-11-10 |
2019-09-12 |
Nektar Therapeutics |
Immunotherapeutic tumor treatment method
|
US10011269B2
(en)
|
2016-11-30 |
2018-07-03 |
Ford Global Technologies, Llc |
Identifying in-range fuel pressure sensor error
|
BR122020025384B1
(pt)
|
2016-12-13 |
2022-07-12 |
Delinia, Inc |
Proteínas de fusão e dimérica, usos das mesmas e composição farmacêutica
|
EP3555125A4
(en)
|
2016-12-15 |
2019-11-20 |
The Brigham and Women's Hospital, Inc. |
TISSUE BIOLOGICAL PRODUCTS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISORDERS
|
WO2018119114A1
(en)
|
2016-12-22 |
2018-06-28 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
US10232053B2
(en)
|
2016-12-30 |
2019-03-19 |
Trieza Therapeutics, Inc. |
Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
|
US11065345B2
(en)
|
2017-01-04 |
2021-07-20 |
Nanotics, Llc |
Methods for assembling scavenging particles
|
WO2018129188A1
(en)
|
2017-01-04 |
2018-07-12 |
Nanotics, Llc |
Methods for assembling scavenging particles
|
US20200121719A1
(en)
|
2017-01-06 |
2020-04-23 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
|
CA3048907C
(en)
|
2017-01-06 |
2023-05-23 |
Nantkwest, Inc. |
Genetically modified nk-92 cells with decreased cd96/tigit expression
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
US10603358B2
(en)
|
2017-01-10 |
2020-03-31 |
Nodus Therapeutics |
Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator
|
US20200000862A1
(en)
|
2017-02-03 |
2020-01-02 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Oncolytic virus therapy
|
JP7200138B2
(ja)
|
2017-02-16 |
2023-01-06 |
ソネット バイオセラピューティクス,インコーポレイテッド |
アルブミン結合ドメイン融合タンパク質
|
EP3589303A4
(en)
|
2017-03-01 |
2020-11-25 |
Nektar Therapeutics |
IMMUNOTHERAPEUTIC TUMOR TREATMENT PROCEDURE USING AN INTERLEUKIN-2 RECEPTOR ALPHA, BETA-SELECTIVE AGONIST IN COMBINATION WITH ADOPTIVE CELL TRANSFER THERAPY
|
KR102619015B1
(ko)
|
2017-03-15 |
2023-12-28 |
큐 바이오파마, 인크. |
면역 반응을 조절하는 방법
|
CN110520436A
(zh)
|
2017-03-15 |
2019-11-29 |
潘迪恩治疗公司 |
靶向免疫耐受性
|
JOP20190224A1
(ar)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
JP7148539B2
(ja)
|
2017-04-03 |
2022-10-05 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
免疫抱合体
|
ES2928718T3
(es)
|
2017-04-03 |
2022-11-22 |
Hoffmann La Roche |
Inmunoconjugados de un anticuerpo anti-PD-1 con una IL-2 mutante o con IL-15
|
CN108686202A
(zh)
|
2017-04-06 |
2018-10-23 |
张晋宇 |
肿瘤免疫疗法
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
KR20190136076A
(ko)
|
2017-04-13 |
2019-12-09 |
에프. 호프만-라 로슈 아게 |
암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
|
BR112019023409A2
(pt)
|
2017-05-10 |
2020-06-16 |
Iovance Biotherapeutics, Inc. |
Métodos para tratar um câncer em um paciente e uma malignidade hematológica, para expandir linfócitos infiltrantes de tumor, linfócitos de sangue periférico e linfócitos infiltrantes de medula, processo para a preparação de uma população de linfócitos infiltrantes de tumor, e, uso de um tumor líquido na fabricação de uma população de linfócitos infiltrantes de tumor.
|
US11913962B2
(en)
|
2017-05-15 |
2024-02-27 |
University Of Miami |
Materials and methods for subjects at risk for viral reactivation
|
CN111107868A
(zh)
|
2017-05-24 |
2020-05-05 |
诺华股份有限公司 |
抗体细胞因子移植蛋白及使用方法
|
JOP20190271A1
(ar)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
US20200270334A1
(en)
|
2017-05-24 |
2020-08-27 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
US20210277085A1
(en)
|
2017-05-24 |
2021-09-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
JP2020521452A
(ja)
|
2017-05-24 |
2020-07-27 |
パンディオン・セラピューティクス・インコーポレイテッド |
標的化免疫寛容
|
EP3635097A1
(en)
|
2017-06-05 |
2020-04-15 |
Iovance Biotherapeutics, Inc. |
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
|
WO2018227018A1
(en)
|
2017-06-07 |
2018-12-13 |
Silverback Therapeutics, Inc. |
Antibody conjugates of immune-modulatory compounds and uses thereof
|
MA49403A
(fr)
|
2017-06-12 |
2021-03-24 |
Obsidian Therapeutics Inc |
Compositions de pde5 et méthodes d'immunothérapie
|
CN110719920B
(zh)
|
2017-06-14 |
2024-01-30 |
苏州丁孚靶点生物技术有限公司 |
蛋白质异二聚体及其用途
|
CN111201035A
(zh)
|
2017-06-19 |
2020-05-26 |
梅迪塞纳医疗股份有限公司 |
Il-2超激动剂、激动剂及其融合体的用途和方法
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
CA3069017A1
(en)
|
2017-07-03 |
2019-01-10 |
Torque Therapeutics, Inc. |
Immunostimulatory fusion molecules and uses thereof
|
JP2020527025A
(ja)
|
2017-07-12 |
2020-09-03 |
シンロジック オペレーティング カンパニー インコーポレイテッド |
腫瘍細胞において免疫モジュレーターおよび抗がん治療剤を産生するようにプログラムされた微生物
|
US20190023760A1
(en)
|
2017-07-24 |
2019-01-24 |
Eth Zurich |
Method for preparing interleukin-2 or interleukin-2 analogues
|
US20200181220A1
(en)
|
2017-08-03 |
2020-06-11 |
Synthorx, Inc. |
Cytokine conjugates for the treatment of proliferative and infectious diseases
|
BR112020001944A2
(pt)
|
2017-08-04 |
2020-08-04 |
Genmab A/S |
agente de ligação, ácido nucleico, vetor de expressão, célula, composição, métodos para tratamento de uma doença e para produção de um anticorpo biespecífico, uso de um agente de ligação, e, anticorpo anti-idiotípico.
|
CA3069930A1
(en)
|
2017-08-09 |
2019-02-14 |
Orionis Biosciences Inc. |
Cd8 binding agents
|
CA3069992A1
(en)
|
2017-08-09 |
2019-02-14 |
Orionis Biosciences Inc. |
Clec9a binding agents and use thereof
|
CN111328286A
(zh)
|
2017-08-09 |
2020-06-23 |
奥里尼斯生物科学有限公司 |
Pd-1和pd-l1结合剂
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
JP2021500852A
(ja)
|
2017-08-18 |
2021-01-14 |
グリットストーン オンコロジー インコーポレイテッド |
共有抗原を標的にする抗原結合タンパク質
|
US20210115453A1
(en)
|
2017-08-31 |
2021-04-22 |
Poseida Therapeutics, Inc. |
Transposon system and methods of use
|
TW201920247A
(zh)
|
2017-09-07 |
2019-06-01 |
美商信號生物製藥公司 |
抗原呈現多肽及其使用方法
|
CA3074839A1
(en)
|
2017-09-07 |
2019-03-14 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
|
BR112020004535A2
(pt)
|
2017-09-07 |
2020-09-08 |
Cue Biopharma, Inc. |
peptídeos moduladores de células t multiméricos e métodos de uso destes
|
TW201925235A
(zh)
|
2017-09-07 |
2019-07-01 |
美商信號生物製藥公司 |
具有化學結合位點之抗原呈現多肽及其使用方法
|
WO2019051424A2
(en)
|
2017-09-08 |
2019-03-14 |
Poseida Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR CONDITIONAL GENE EXPRESSION MEDIATED BY A CHIMERIC LIGAND RECEPTOR (CLR)
|
AU2018338608A1
(en)
|
2017-09-27 |
2020-04-09 |
Sigilon Therapeutics, Inc. |
Methods, compositions, and implantable elements comprising active cells
|
CN117430699A
(zh)
|
2017-09-30 |
2024-01-23 |
合肥立方制药股份有限公司 |
结合至纤维连接蛋白b结构域的蛋白
|
US11474271B2
(en)
|
2017-10-24 |
2022-10-18 |
Schlumberger Technology Corporation |
Methods and systems for automated sonic imaging
|
WO2019084284A1
(en)
|
2017-10-27 |
2019-05-02 |
Coneksis, Inc. |
NK CELLS FOR USE IN THE TREATMENT OF CANCER IN DOGS
|
CA3081539A1
(en)
|
2017-11-08 |
2019-05-16 |
Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. |
Conjugates of biomolecule and use thereof
|
WO2019092504A1
(en)
|
2017-11-13 |
2019-05-16 |
Extremochem, Lda. |
Neutral glycosylated amides and dianionic glucuronidated acids as stabilizers for biological molecules
|
BR112020009663A2
(pt)
|
2017-11-17 |
2020-11-10 |
Iovance Biotherapeutics, Inc. |
método para a expansão de linfócitos infiltrantes de tumor (tils) em uma população terapêutica de tils, método para o tratamento de um indivíduo com câncer, composição
|
AU2018372167B2
(en)
|
2017-11-21 |
2023-12-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Partial agonists of interleukin-2
|
JP2021503885A
(ja)
|
2017-11-22 |
2021-02-15 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
末梢血からの末梢血リンパ球(pbl)の拡大培養
|
SG11202003965VA
(en)
|
2017-12-06 |
2020-06-29 |
Pandion Therapeutics Inc |
Il-2 muteins and uses thereof
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
WO2019113221A1
(en)
|
2017-12-06 |
2019-06-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Engineered proteins to enhance sensitivity of a cell to il-2
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
JP2021505156A
(ja)
|
2017-12-06 |
2021-02-18 |
パンディオン・オペレーションズ・インコーポレイテッド |
標的化免疫寛容
|
US20190175651A1
(en)
|
2017-12-13 |
2019-06-13 |
Janssen Biotech, Inc. |
Immortalized car-t cells genetically modified to elminate t-cell receptor and beta 2-microglobulin expression
|
JP2021508104A
(ja)
|
2017-12-15 |
2021-02-25 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法
|
MX2020006322A
(es)
|
2017-12-19 |
2020-09-18 |
Xencor Inc |
Proteinas de fusion il-2 fc modificadas.
|
EP3502139A1
(en)
|
2017-12-19 |
2019-06-26 |
Philogen S.p.A. |
Antibodies to tumour antigens
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
US11629189B2
(en)
|
2017-12-19 |
2023-04-18 |
Kymab Limited |
Bispecific antibody for ICOS and PD-L1
|
JP2021507703A
(ja)
|
2017-12-20 |
2021-02-25 |
ポセイダ セラピューティクス,インコーポレイティド |
Vcar組成物とその利用法
|
EP3733716A4
(en)
|
2017-12-26 |
2021-11-24 |
Nanjing GenScript Biotech Co., Ltd. |
DIMERAL FUSION PROTEIN USING ANTIBODY FC REGION AS A SKELETON AND ASSOCIATED USE
|
US20210060169A1
(en)
|
2017-12-27 |
2021-03-04 |
Kyowa Kirin Co., Ltd. |
Il-2 variant
|
EP3732197A1
(en)
|
2017-12-28 |
2020-11-04 |
Julius-Maximilians-Universität Würzburg |
TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCyR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCyR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA)
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
CA3087771A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
CN111886241A
(zh)
|
2018-01-09 |
2020-11-03 |
库尔生物制药有限公司 |
多聚体t细胞调节多肽及其使用方法
|
JP2021511348A
(ja)
|
2018-01-24 |
2021-05-06 |
ベイジン パーカンズ オンコロジー カンパニー リミテッド |
サイトカイン融合タンパク質
|
WO2019144309A1
(en)
|
2018-01-24 |
2019-08-01 |
Beijing Percans Oncology Co. Ltd. |
Cytokine Fusion Proteins
|
AR114127A1
(es)
|
2018-03-02 |
2020-07-22 |
Lilly Co Eli |
Anticuerpos agonistas contra pd-1 y usos de estos
|
MX2020009309A
(es)
|
2018-03-07 |
2021-01-08 |
Poseida Therapeutics Inc |
Composiciones de cartirina y métodos para su uso.
|
CN113166220A
(zh)
|
2018-03-09 |
2021-07-23 |
奥美药业有限公司 |
创新细胞因子前药
|
EP3820499A4
(en)
|
2018-07-09 |
2022-07-13 |
Surrozen Operating, Inc. |
TISSUE-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND THEIR USES
|
KR20210038549A
(ko)
|
2018-07-24 |
2021-04-07 |
비온테크 알엔에이 파마슈티컬스 게엠베하 |
Il2 작용제
|
WO2020061142A1
(en)
|
2018-09-18 |
2020-03-26 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
US20220106398A1
(en)
|
2019-02-08 |
2022-04-07 |
Igm Biosciences, Inc. |
Anti-gitr antigen-binding domains and uses thereof
|
BR112021023345A2
(pt)
|
2019-05-20 |
2022-02-01 |
Pandion Operations Inc |
Imunotolerância com alvo em madcam
|
US11095944B2
(en)
|
2019-08-19 |
2021-08-17 |
Roku, Inc. |
Content-modification system with broadcast schedule utilization feature
|
EP4017595A4
(en)
|
2019-08-19 |
2023-12-20 |
Pandion Operations, Inc. |
TARGETED IMMUNOTOLERANCE WITH A PD-1 AGONIST
|
US20230235004A1
(en)
|
2020-02-21 |
2023-07-27 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with pd-1 agonists or il-2 muteins
|
US20210269496A1
(en)
|
2020-02-21 |
2021-09-02 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a cd39 effector
|
MX2023002045A
(es)
|
2020-08-19 |
2023-05-08 |
Pandion Operations Inc |
Anticuerpos anti-pd-1 multiparatopicos y usos de los mismos.
|
WO2022082019A2
(en)
|
2020-10-16 |
2022-04-21 |
Pandion Operations, Inc. |
Kidney targeted immunotolerance
|
EP4229078A2
(en)
|
2020-10-16 |
2023-08-23 |
Pandion Operations, Inc. |
Skin targeted immunotolerance
|